Scarica l'app Stockscreener
75.85
0.59%
-0.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.25
Aprire:
$76.41
Volume 24 ore:
149.93K
Relative Volume:
0.33
Capitalizzazione di mercato:
$1.70B
Reddito:
$747.40M
Utile/perdita netta:
$-12.60M
Rapporto P/E:
-98.67
EPS:
-0.7687
Flusso di cassa netto:
$105.18M
1 W Prestazione:
-6.99%
1M Prestazione:
-10.13%
6M Prestazione:
-14.19%
1 anno Prestazione:
+27.02%
Intervallo 1D:
$75.30
$76.59
Intervallo di 1 settimana:
$75.30
$82.42
Portata 52W:
$54.10
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Nome
Ani Pharmaceuticals Inc
Settore
Telefono
(218) 634-3500
Indirizzo
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
75.86 | 1.71B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.35 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.25 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-03-12 | Iniziato | JP Morgan | Overweight |
| 2024-12-11 | Iniziato | Leerink Partners | Outperform |
| 2024-10-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-15 | Iniziato | CapitalOne | Overweight |
| 2023-08-22 | Reiterato | H.C. Wainwright | Buy |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-02 | Iniziato | Truist | Buy |
| 2020-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-05-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Reiterato | Canaccord Genuity | Buy |
| 2017-07-31 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-22 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Iniziato | Raymond James | Strong Buy |
| 2016-05-24 | Downgrade | Standpoint Research | Buy → Hold |
| 2015-11-13 | Iniziato | Standpoint Research | Buy |
| 2015-09-28 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
| 2015-08-04 | Reiterato | ROTH Capital | Neutral |
| 2015-07-31 | Reiterato | Oppenheimer | Outperform |
| 2015-07-15 | Reiterato | ROTH Capital | Neutral |
| 2015-06-23 | Reiterato | Oppenheimer | Outperform |
| 2015-05-18 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Reiterato | Oppenheimer | Outperform |
| 2015-04-10 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Reiterato | ROTH Capital | Buy |
| 2015-02-18 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
Aug Wrap: Will ANI Pharmaceuticals Inc stock go up in YEARMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Is ANI Pharmaceuticals (ANIP) Pricing Reflect Long Term Value After Strong Multi Year Returns - Yahoo Finance
Thrivent Financial for Lutherans Has $5.32 Million Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ranger Investment Management L.P. Decreases Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Pricing Reflect Long Term Cash Flow Potential? - Sahm
ANI Pharmaceuticals Pivots to High-Value Rare Disease Treatments - AD HOC NEWS
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Promising 37.97% Upside Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals, Inc. $ANIP is Lisanti Capital Growth LLC's 5th Largest Position - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Did 53.60% Revenue Growth and Portfolio Expansion Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative? - Sahm
Trading Action: Is ANI Pharmaceuticals Inc exposed to political riskJuly 2025 Gainers & Reliable Volume Spike Alerts - baoquankhu1.vn
ANI Pharmaceuticals (ANIP) Stock Analysis: Exploring A 35.71% Potential Upside - DirectorsTalk Interviews
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo Finance
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Investors Don't See Light At End Of ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Tunnel - 富途牛牛
40 Under 40: Kevin Chan, ANI Pharmaceuticals - Medical Marketing and Media
ANI Pharmaceuticals, Inc. (ANIP): Investor Outlook With A Promising 30% Upside Potential - DirectorsTalk Interviews
Breakout Move: Does ANI Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Mizuho Markets Americas LLC - MarketBeat
Aug Setups: What is the next catalyst for SEALPRAQuarterly Earnings Report & Technical Pattern Based Signals - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Invests $1.60 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed? - Sahm
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? - Eastern Progress
ANIP Stock Rises 7% in a Week: Here's What You Should Know - Eastern Progress
Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP) - The Globe and Mail
SG Americas Securities LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 7.0% After Raising 2026 Revenue Outlook and Expanding Rare Disease Team - Yahoo Finance
Insider Sell Alert: Meredith Cook Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals’ Cook sells $42,165 in stock By Investing.com - Investing.com Australia
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock - MarketBeat
Ani Pharmaceuticals’ Cook sells $42,165 in stock - Investing.com
ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Stock Dips on Profit-Taking After 2026 GuidanceNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Finviz
Dow Theory LettersANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - FinancialContent
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance (NASDAQ:ANIP) - Seeking Alpha
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade - The Globe and Mail
Growth Review: Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Performance Recap & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Fund Flows: Why ANI Pharmaceuticals Inc stock remains undervaluedEarnings Risk Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
ANI Pharmaceuticals, Inc. (ANIP) Investor Outlook: Exploring a 29.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Decker Retirement Planning Inc. Boosts Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals expects over $1 billion in 2026 revenue By Investing.com - Investing.com Nigeria
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - Finviz
The Sun: Local News, Sports and Things to DoWhy ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - FinancialContent
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap UpTime to Buy? - MarketBeat
Ani Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance - MarketBeat
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities - The Manila Times
ANI Pharmaceuticals expects over $1 billion in 2026 revenue - Investing.com
Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
8.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):